Novel Science

Cirmtuzumab

Publications

Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody (Zhang et al., PNAS 2019)

Phase 1 Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia (Choi et al, Cell Stem Cell, 2018)

Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma (Yu et al., Oncotarget 2018)

MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia (Rasenti et al., PNAS 2017)

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1 (Choi et al., Clinical Lymphoma, Myeloma & Leukemia 2015)

Ovarian Cancer Stem Cells Express ROR1, Which Can Be Targeted for Anti-Cancer-Stem-Cell Therapy (Zhang et al., PNAS 2014)

The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers (Zhang et al. , Am J Pathol 2012)

Conference Presentations

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the CIRLL Phase 1/2 Trial for CLL and MCL (Choi et al,. ASH Annual Meeting 2019)

A Phase 1b Trial of Cirmtuzumab and Paclitaxel in Locally Advanced /Unresectable or Metastatic Her2 Negative Breast Cancer (Shatsky et al., San Antonio Breast Cancer Symposium 2019)

TK216

Publications

Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma (Zöllner et al., Science Signaling 2017)

YK-4-279 Effectively Antagonizes EWS-FLI1 Induced Leukemia in a Transgenic Mouse Model (Minas et al., Oncotarget 2015)

A Small Molecule Inhibitor of ETV1, YK-4-279, Prevents Prostate Cancer Growth and Metastasis in a Mouse Xenograft Model (Rahim et al., PLoS One 2014)

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma (Erzikan et al., Nature Medicine 2009)

Conference Presentations

A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma (Meyers, CTOS 2019)

The ETS inhibitors YK-4-279 and TK216 interfere with SPIB and synergize with lenalidomide in diffuse large B cell lymphoma of the activated B cell-like type (ABC DLBCL) (Chung et al., ASH Annual Meeting 2017)

CAR-T

Conference Presentations

Preclinical Evaluation of Anti-ROR1 CAR T-cells Employing a ROR1 Binding scFv Derived From the Clinical Stage mAb Cirmtuzumab (Prussak et al., 2020 ASCO-SITC Clinical Immuno-Oncology Symposium)